Bone: Will breast cancer chemoprevention stand on 'solid bone'? Academic Article uri icon

abstract

  • Aromatase inhibitors are the most effective agents for preventing breast cancer; however, their use is associated with bone loss and an increased risk of fractures. Sestak and colleagues show that administration of an oral bisphosphonate prevents aromatase-inhibitor-induced bone loss in postmenopausal women with osteopenia or osteoporosis who are at high risk of breast cancer.

published proceedings

  • Nat Rev Endocrinol

altmetric score

  • 22.63

author list (cited authors)

  • Suva, L. J., & Makhoul, I.

citation count

  • 2

complete list of authors

  • Suva, Larry J||Makhoul, Issam

publication date

  • March 2015